uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Loss of ASRGL1 expression is an independent biomarker for disease-specific survival in endometrioid endometrial carcinoma
Uppsala University, Science for Life Laboratory, SciLifeLab. Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Show others and affiliations
2015 (English)In: Gynecologic Oncology, ISSN 0090-8258, E-ISSN 1095-6859, Vol. 137, no 3, 529-537 p.Article in journal (Refereed) Published
Abstract [en]

Objective. For endometrial carcinoma, prognostic stratification methods do not satisfactorily identify patients with adverse outcome. Currently, histology, tumor grade and stage are used to tailoring surgical treatment and to determine the need for adjuvant treatment Low-risk patients are not considered to require adjuvant therapy or staging lymphadenectomy. For patients with intermediate or high risk, some guidelines recommend tailoring adjuvant treatment according to additional negative prognostic factors. Our objective was to evaluate the biomarker potential of the ASRGL1 protein in endometrial carcinoma. Methods. Using The Human Protein Atlas (www.proteinatlas.org), the L-asparaginase (ASRGL1) protein was identified as an endometrial carcinoma biomarker candidate. ASRGL1 expression was immunohistochemically evaluated with an extensively validated antibody on two independent endometrial carcinoma cohorts (n = 229 and n = 286) arranged as tissue microarrays. Staining results were correlated with clinical features. Results. Reduced expression of ASRGL1, defined as <75% positively stained tumor cells, was significantly associated with poor prognosis and reduced disease-specific survival in endometrioid endometrial adenocarcinoma (EEA). In multivariate analysis the hazard ratios for disease-specific survival were 3.55 (95% CI = 1.10-11.43; p = 0.003) and 323 (95% Cl = 1.53-6.81; p = 0.002) in the two cohorts, respectively. Of the 48 cases with Grade 3 Stage I tumor all disease-related deaths were associated with low ASRGL1 expression. Conclusions. Loss of ASRGL1 in EEA is a powerful biomarker for poor prognosis and retained ASRGL1 has a positive impact on survival. ASRGL1 immunohistochemistry has potential to become an additional tool for prognostication in cases where tailoring adjuvant treatment according to additional prognostic factors besides grade and stage is recommended.

Place, publisher, year, edition, pages
2015. Vol. 137, no 3, 529-537 p.
Keyword [en]
Biomarker, Endometrial cancer, Immunohistochemistry, Prognostic, Tissue microarray, Pathology
National Category
Cancer and Oncology Obstetrics, Gynecology and Reproductive Medicine
URN: urn:nbn:se:uu:diva-258030DOI: 10.1016/j.ygyno.2015.03.055ISI: 000355779000028PubMedID: 25858696OAI: oai:DiVA.org:uu-258030DiVA: diva2:841304
Knut and Alice Wallenberg Foundation, 2008.0143Swedish Cancer Society, 2012/598
Available from: 2015-07-13 Created: 2015-07-10 Last updated: 2015-07-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Edqvist, Per-Henrik D.Ponten, Fredrik
By organisation
Science for Life Laboratory, SciLifeLabDepartment of Immunology, Genetics and Pathology
In the same journal
Gynecologic Oncology
Cancer and OncologyObstetrics, Gynecology and Reproductive Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 126 hits
ReferencesLink to record
Permanent link

Direct link